Fosamprenavir: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
* Drug Class: [[HIV Protease]] Inhibitor | * Drug Class: [[HIV Protease]] Inhibitor | ||
* Date of FDA Approval (Discontinued): 2003 (2017) <br /> | * Date of FDA Approval (Discontinued): 2003 (2017) <br /> | ||
* | * 2007 Sales: $240 Million | ||
* Importance: As a prodrug, It is rapidly metabolized by the liver into its active form, also known as [[Amprenavir]]. As a prodrug, it is a slow release form of Amprenavir, thus requiring less frequent dosing. It was one of the first instances of a successful drug stemming from joint ventures of major pharmaceutical companies. | * Importance: As a prodrug, It is rapidly metabolized by the liver into its active form, also known as [[Amprenavir]]. As a prodrug, it is a slow release form of Amprenavir, thus requiring less frequent dosing. It was one of the first instances of a successful drug stemming from joint ventures of major pharmaceutical companies. | ||
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | ||
===Mechanism of Action=== | ===Mechanism of Action=== | ||
As a prodrug form of Amprenavir, it has an identical mechanism of action as [[Amprenavir]]. | |||
===Drug Resistance=== | ===Drug Resistance=== | ||
